Ozempic Medicare Cost: What Taxpayers Are Paying for GLP-1 Drugs in 2026

Ozempic has become one of the most talked-about drugs in America — and one of the most expensive for taxpayers. As a Medicare-covered diabetes medication that also produces dramatic weight loss, semaglutide sits at the center of a multi-billion dollar policy debate: How much should the federal government pay for drugs that millions of Americans want, but that cost over $1,000 per month each?

The Taxpayer Tab: GLP-1 Drug Costs in Medicare

Here's what Medicare — funded by taxpayer dollars and beneficiary premiums — is spending on GLP-1 receptor agonist drugs:

Why Ozempic Costs So Much

At approximately $1,347 per prescription fill, Ozempic is not a specialty drug in the traditional sense — it's a mass-market medication at specialty prices. A single patient on Ozempic costs Medicare roughly $12,000-17,000 per year. Multiply that by 517,958 patients in the dataset, and you get $4.30B in Medicare spending on one drug.

Several factors keep Ozempic expensive:

• No generic competition: Semaglutide is a complex injectable peptide. The first biosimilar isn't expected until 2031 or later, giving Novo Nordisk nearly 15 years of market exclusivity.
• Duopoly pricing: Only two companies — Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound) — dominate the GLP-1 market, limiting competitive pressure.
• Massive demand: The combination of clinical efficacy and cultural awareness has created unprecedented patient demand that manufacturers have leveraged to maintain premium pricing.
• U.S. pricing structure: The same drug costs $90/month in the UK and $185-220 in Canada. American taxpayers pay 3-10x more for identical medication.

The Coverage Gap: Diabetes vs. Weight Loss

Here's the policy tension at the heart of the Ozempic cost debate: Medicare covers Ozempic for type 2 diabetes, but it does not cover the same molecule (Wegovy) when prescribed for weight loss. This creates a two-tier system:

The statutory exclusion of anti-obesity medications from Medicare Part D dates to 2003, when weight loss drugs were considered cosmetic. Two decades later, the science has changed dramatically — obesity is recognized as a chronic disease, and GLP-1 drugs reduce cardiovascular events, kidney disease, and mortality. But the law hasn't caught up.

Multiple bills — including the Treat and Reduce Obesity Act — have been introduced to repeal the exclusion. None have passed. The reason is fiscal: the Congressional Budget Office estimates that covering anti-obesity medications for all eligible beneficiaries would cost $35-50 billion over ten years. Some independent estimates are far higher.

What Would Full Obesity Coverage Cost Taxpayers?

The numbers are staggering. Over 40 million Medicare beneficiaries are overweight or obese. If even a fraction sought GLP-1 prescriptions:

These costs would flow through to all Medicare beneficiaries via higher Part D premiums, and to taxpayers through increased federal spending. The IRA's $2,000 out-of-pocket cap means the federal government — not patients — absorbs most of the cost increase for expensive drugs, shifting the burden directly to the national budget.

Supporters argue that preventing obesity-related conditions (heart attacks, strokes, joint replacements, dialysis) would save Medicare money in the long run. This may be true over 15-20 years, but the CBO's 10-year budget window captures the costs immediately while the savings accrue gradually. It's the classic government budgeting problem: pay now, save later — but "later" doesn't fit in the scoring window.

Price Negotiation: Will the IRA Help?

The Inflation Reduction Act authorized Medicare to negotiate drug prices for the first time. Ozempic was selected among the next batch of drugs for price negotiation, with negotiated prices expected in 2027. Based on the first round of negotiations (which achieved 38-79% discounts), Ozempic's Medicare price could drop to $300-600 per month.

But negotiated prices only help if volume doesn't overwhelm the savings. A 50% price cut is negated if patient volume triples — which is exactly the trajectory GLP-1 drugs are on. The math is simple: lower per-unit costs × higher volume can still equal higher total spending. This is the fundamental challenge the IRA faces with blockbuster drug categories.

For more on how the IRA affects drug costs: See all IRA-negotiated drugs →

International Price Comparison: What Other Countries Pay

Novo Nordisk is profitable in every market it operates in — the company's operating profit margin exceeds 40%. The US price is not necessary to fund R&D; it's what the market bears in the absence of price regulation. American taxpayers effectively subsidize pharmaceutical profits through higher Medicare spending.

Who Prescribes the Most Ozempic?

Ozempic is prescribed by an unusually wide range of providers — 71,812 individual prescribers in our dataset. This is not a concentrated prescribing pattern like opioids; it's broadly distributed across the healthcare system:

• Endocrinologists prescribe the most per provider but are a small group
• Internal medicine and family practice drive the highest absolute volume
• Nurse practitioners and PAs are a significant and growing share of prescribers
• Geographic concentration follows diabetes prevalence — highest in Southern and Midwestern states

Explore individual prescriber data: Search Medicare prescribers →

The Mounjaro Factor

While Ozempic dominates the headlines, Eli Lilly's Mounjaro (tirzepatide) may be the bigger long-term cost driver. With 73,129 patients and $877.9M in spending during its launch year, Mounjaro is on pace to rival Ozempic within 2-3 years. Its dual-receptor mechanism produces greater weight loss and blood sugar control than semaglutide, driving rapid adoption and provider switching.

Together, Ozempic and Mounjaro represent a new reality for Medicare: two drugs from two companies that could collectively cost more than any other drug category in the program within a few years.

The Bottom Line for Taxpayers

The GLP-1 cost challenge is the defining drug policy question of this decade. The drugs are genuinely effective — perhaps the most broadly beneficial pharmaceutical advance in years. But at current prices and growing volume, they threaten to consume an ever-larger share of the Medicare budget. The answer isn't to deny patients effective treatment. It's to fix the pricing system that makes these drugs 10x more expensive in America than anywhere else in the world.

Frequently Asked Questions